FDA green-lights tirzepatide, marketed as Zepbound, for chronic weight management
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers
Bhanusali, who uses red-light treatments on patients in his office
Thanks Love it
Ten commissioners voted to nix GLP-1 drug coverage for weight loss, aligning with a benefit change already embraced by commercial insurers and the Massachusetts Interlocal Insurance Association
They could be sharing vials, and needles, using the same gloves for multiple patients, not correctly cleaning their premises, or not correctly preparing the area theyre treating